MYGN - Myriad Genetics Inc

Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.

52W High

$29.30

52W Low

$3.76

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.94

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

47.17

EV/EBITDA (<8 favorable)

-23.47

EV/Revenue (<3 favorable)

0.84

P/S (TTM) (<3 favorable)

0.74

P/B (<3 favorable)

1.59

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

2.90%

Institutions (25–75% balanced)

98.38%

Shares Outstanding

93,045,000

Float

85,689,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

832,900,000

Gross Profit (TTM)

586,600,000

EPS (TTM)

-4.31

Profit Margin (>10% good)

-0.47%

Operating Margin (TTM) (higher better)

-0.06%

ROE (TTM) (>15% strong)

-0.70%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.01

Momentum

Bearish momentum

Value

0.5925

0.5916

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025